Korro Bio, Inc. (KRRO) NASDAQ
13.46
-0.45(-3.24%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
13.46
-0.45(-3.24%)
Currency In USD
| Previous Close | 13.91 |
| Open | 14.5 |
| Day High | 14.5 |
| Day Low | 13.31 |
| 52-Week High | 55.89 |
| 52-Week Low | 5.2 |
| Volume | 129,656 |
| Average Volume | 255,481 |
| Market Cap | 126.52M |
| PE | -1.08 |
| EPS | -12.48 |
| Moving Average 50 Days | 11.75 |
| Moving Average 200 Days | 18.63 |
| Change | -0.45 |
Korro Announces Oversubscribed $85 Million Private Placement
GlobeNewswire Inc.
Mar 09, 2026 11:30 AM GMT
Financing led by new investor Venrock Healthcare Capital Partners, with participation from new and existing investors Proceeds support the achievement of value inflection points for multiple RNA editing programs including reporting clinical data for:
Korro to Present at the TD Cowen 46th Annual Health Care Conference
GlobeNewswire Inc.
Feb 25, 2026 9:05 PM GMT
CAMBRIDGE, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a biopharmaceutical company developing a new class of genetic medicines based on editing RNA for rare and highly prevalent diseases, today announced that Ra
Korro to Host Virtual Analyst Day on January 27, 2026
GlobeNewswire Inc.
Jan 20, 2026 1:00 PM GMT
- Program to feature presentations from the company management about KRRO-121 for the potential treatment of hyperammonemia, a leading clinical hepatologist about ammonia-driven diseases, and a caregiver sharing perspectives on living with urea cycle